- Sight Sciences Inc SGHT announced 36-month post-surgery follow-up results of the OMNI Surgical System.
- The data demonstrates that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis.
- The study showed that canaloplasty followed by trabeculectomy using the OMNI Surgical System achieved a mean reduction in intraocular pressure (IOP) of at least 20% for all 26 patients (38 eyes) at 36 months follow-up.
- The post-operative IOP and medication use reduction at 12 months remained consistent over three years, suggesting robust, durable effectiveness of the OMNI Surgical System.
- A minimal number of adverse events were reported, all resolved without intervention except one eye required secondary IOP lowering intervention.
- Price Action: SGHT shares are down 2.86% at $8.51 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in